Company news

Damora Therapeutics, Inc. news in 2026

Damora Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 5, 2026

Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

November 4, 2026

Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting

November 4, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

October 5, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 10, 2026

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

August 5, 2026

Damora Announces Redomestication from Delaware to Cayman Islands

July 17, 2026

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

May 4, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 30, 2026

Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

March 23, 2026

Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

March 19, 2026

Decks in 2026